Dna-pk inhibitors
US-2015111871-A1 · Apr 23, 2015 · US
DNA-PK inhibitors
US9376448B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9376448-B2 |
| Application number | US-201314056560-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 17, 2013 |
| Priority date | Apr 24, 2012 |
| Publication date | Jun 28, 2016 |
| Grant date | Jun 28, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, wherein the compound is: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient. 3. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 6. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 7. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable excipient. 8. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable excipient. 9. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable excipient. 10. A pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9376448B2 cover?
- The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
- Who is the assignee on this patent?
- Vertex Pharma
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).